Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020109428 - THERAPEUTIC COMPOUNDS, NANOPARTICLES AND USES THEREOF

Publication Number WO/2020/109428
Publication Date 04.06.2020
International Application No. PCT/EP2019/082810
International Filing Date 27.11.2019
IPC
A61K 47/69 2017.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
69the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61P 35/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
CPC
A61K 47/549
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
54the modifying agent being an organic compound
549Sugars, nucleosides, nucleotides or nucleic acids
A61K 47/6923
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
69the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
6921the form being a particulate, a powder, an adsorbate, a bead or a sphere
6923the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
A61K 47/6929
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
69the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
6921the form being a particulate, a powder, an adsorbate, a bead or a sphere
6927the form being a solid microparticle having no hollow or gas-filled cores
6929the form being a nanoparticle, e.g. an immuno-nanoparticle
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
C07D 498/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
498Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
Applicants
  • MIDATECH LTD [GB]/[GB]
Inventors
  • PORTER, John
  • DING, Yao
Agents
  • MEWBURN ELLIS LLP
Priority Data
1819430.829.11.2018GB
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) THERAPEUTIC COMPOUNDS, NANOPARTICLES AND USES THEREOF
(FR) COMPOSÉS THÉRAPEUTIQUES, NANOPARTICULES ET LEURS UTILISATIONS
Abstract
(EN)
The present invention comprising a maytansinoid covalently bonded to a linker group, wherein the linker group is covalently bonded to a ligand group having a cyclic polythiol moiety. Also provided are nanoparticles and conjugates, including antibody-drug conjugates, comprising the compound. Furthermore, pharmaceutical compositions comprising the compounds, nanoparticles, and conjugates are provided. Also disclosed are uses of the compounds, nanoparticles, conjugates and pharmaceutical compositions in methods of treatment of proliferative disorders, including cancer.
(FR)
La présente invention comprend un maytansinoïdes lié de manière covalente à un groupe lieur, le groupe lieur étant lié de manière covalente à un groupe ligand ayant une fraction polythiol cyclique. L'invention concerne également des nanoparticules et des conjugués, y compris des conjugués anticorps-médicament, comprenant le composé. L'invention concerne en outre des compositions pharmaceutiques comprenant les composés, les nanoparticules et les conjugués. L'invention concerne également des utilisations des composés, des nanoparticules, des conjugués et des compositions pharmaceutiques dans des procédés de traitement de troubles prolifératifs, y compris le cancer.
Latest bibliographic data on file with the International Bureau